… patients will develop some degree of oral mucositis. In recent studies, severe oral mucositis
occurred in 29% to 66% of all patients receiving radiation therapy for head and neck cancer […

… in basic oral care interventions to update evidence-based practice guidelines for preventing
and treating oral mucositis (OM) in cancer patients undergoing radio- or chemotherapy. …

… on mucositis development and pointing out the limits and the benefits of current mucositis …
of the existing biomarkers to predict patient risk of developing oral mucositis and their role in …

… Most head and neck cancer patients are treated with RT, … cancer patients receiving
conventional fractionated RT (one dose/day, 5 days/week for 5–7 weeks) and in 100% of patients …

… Oral mucositis (OM) is a distressing toxic effect of chemotherapy and radiotherapy. It can
increase the … Oral mucositis (OM) is a common side effect in patients with cancer treated with …

… affected patients. Furthermore, the prevention and control of oral mucositis are vital for cancer
… temporary or permanent treatment discontinuation and compromise cancer control (1,4,8). …

… The patient was unable to eat solid foods and oral mucositis was graded III on WHO scale. …
hypofractionated radiotherapy, but in the majority of patients mucositis resolves much faster. …

… in the oral cavity. Common complaints of patients related to oral mucositis include changes
in … Often patients experience a cluster or constellation of signs and symptoms including pain, …

… The incremental cost of mucositis in patients with head and neck cancer is more than $17
000 (US). Much has been learned about the pathobiology that underlies the condition. The …

… administered orally in the prevention of oral mucositis in oral cancer patients receiving …
glutamine for the prevention of oral mucositis in patients receiving high-dose chemotherapy …